Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell
• Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Benchmark Reiterates Buy on Biofrontera, Lowers Price Target to $7
Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $11 to $7.
Biofrontera Has Received A Notice Of Allowance For Its U.S. Patent Application 17/269,816 Titled “Photodynamic Therapy Comprising Two Light Exposures At Different Wavelengths (For The Prevention Or Treatment Of Dermatological Disease)”
https://patentcenter.uspto.gov/applications/17269816/ifw/docs
Biofrontera To Launch Phase 3 Clinical Study Evaluating Ameluz-PDT For The Treatment Of Actinic Keratosis On The Extremities, Neck and Trunk
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled,
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Biofrontera Inc. Fully Exercises Recently Acquired Options To Purchase Shares Of Biofrontera AG
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the exercise in full of options to purchase 2,623,365 ordinary shares of
Biofrontera Sees Q3 Product Revenues $4.3M
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary unaudited product revenues for the three and nine
